<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335046">
  <stage>Registered</stage>
  <submitdate>27/01/2010</submitdate>
  <approvaldate>2/02/2010</approvaldate>
  <actrnumber>ACTRN12610000103066</actrnumber>
  <trial_identification>
    <studytitle>Study for the assessment of clinical non-inferiority and tolerability of  different conjugated estrogen vaginal cream ESTROGENON (Sanval Comercio e Industria Ltda) versus PREMARIN (Wyeth Industria Farmaceutica Ltda) in women post menopause.</studytitle>
    <scientifictitle>Study for the assessment of clinical non-inferiority and tolerability of different conjugated estrogen vaginal cream ESTROGENON (Sanval Comercio e Industria Ltda) versus PREMARIN (Wyeth Industria Farmaceutica Ltda) in women post menopause.</scientifictitle>
    <utrn>U1111-1113-4033</utrn>
    <trialacronym>CEBIO_11_2008</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Study with the purpose of check clinical non-inferiority and tolerance of two vaginal cream based on the conjugated estrogen manufactured by different manufacturers.</healthcondition>
    <healthcondition>Women in post menopause with indications for estrogen replacement therapy.</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Estrogenon (conjugated estrogens), vaginal cream 0,625mg/g manufactured by Sanval Comercio e Industria Ltda,administered once a each two days for a total of 90 days, applied with cream disposable applicator, in comparasion to Premarin(Estrogen conjugated) 0,625 mg/g manufactured by Wyeth Industria Farmaceutica Ltda, taken once the each two days for a total of 90 days, administrated by cream disposable applicator.</interventions>
    <comparator>Comparison of action of two differents vaginal cream of conjugated estrogens 0625mg/g, taken once the each two days, during 90 days on a clinical setting and administrated by cream disposable applicator.</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Endometrium thickness - test used: transvaginal ultrasound exam</outcome>
      <timepoint>90 days following randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Alterations in clinical examination (gynecological) - Citology</outcome>
      <timepoint>90 days following randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women in post menopause with indications for estrogen replacement therapy</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Patients with contraindications for estrogen use</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanval Comercio e Industria Ltda.</primarysponsorname>
    <primarysponsoraddress>R. Lagrange, 401 _ Bairro Socorro
Sao Paulo - Brazil - 04802-000</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sanval Comercio e Industria Ltda.</fundingname>
      <fundingaddress>R. Lagrange, 401 _ Bairro Socorro
Sao Paulo - Brazil - 04761-050</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients at post-menopause phase, after signing Free and Informed Consent Term, shall pass through medical consultation and laboratorial exams (clinical analysis) including plasmatic dosing of Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), Glutamate Oxaloacetate Transaminase (GOT) and glutamic-pyruvic transaminase (GPT), calcium and Total Estrogen (Estradiol) and Free Estrogen (Free Estriol), Glucose and total Cholesterol. A mammography will be performed in order to exclude patients with counter indication for the drug use. Patients shall be sent to undergo transvaginal ultrasound exam in order to assess their endometrium thickness. During medical consultation, vaginal walls as well as the cervix will be scraped for functional cytological and oncologic exam, using Papanicolaou test method. The procedures, in total or in part, shall be repeated at the following visits, within three months follow-up time period.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica em Pesquisa do Hospital Belo Horizonte</ethicname>
      <ethicaddress />
      <ethicapprovaldate>9/03/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Marco Tulio Baccarini Pires PhD</name>
      <address>Av. Contorno 2646 - 6ยบ andar - Belo Horizonte - Minas Gerais - 30110-014</address>
      <phone>+553132413458</phone>
      <fax>+553132413458</fax>
      <email>mtbpires@cebio.med.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jose Aurelio Quintao Sarmento</name>
      <address>Av. Nicolau Alayon 441 - Interlagos - Sao Paulo - Sao Paulo -04802-000</address>
      <phone>+551156604001</phone>
      <fax>+551156668664</fax>
      <email>aurelio.sarmento@sanval.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>